Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice
OpenAlex – April 14, 2025
Source: OpenAlex
Summary
Prolonged low-dose LSD, a focus in Psychedelics and Drug Studies, revealed no cardiovascular risk in mice. Using Biochemical Analysis and Sensing Techniques, heart health was monitored after chronic administration of very low doses. While serotonin, known to activate specific neurotransmitter receptors linked to heart issues, caused significant heart wall thickening at 4 and 8 weeks, LSD groups showed no such changes. Pharmacology indicated LSD's influence on these receptors was substantial but brief, unlike heart-damaging substances. This offers critical Medicine insights into microdosed psychedelics' safety profile and Neurotransmitter Receptor Influence on Behavior.
Abstract
Summary Microdosing, the prolonged ingestion of psychedelics at sub-hallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT 2B receptors, which cause heart disease with strong chronic activation. We investigated the effects of microdosed psychedelics on cardiovascular health in mice using electrocardiography after chronically administering either serotonin as a positive control or lysergic acid diethylamide (LSD) at two sub-hallucinogenic doses. Serotonin produced significant ventricular thickening at 4- and 8-weeks. No significant changes were observed in vehicle or LSD groups. We determined the affinity and potency of LSD, psilocybin, and norfenfluramine at mouse and human 5-HT 2B Rs and observed no significant differences. We calculated that levels of 5-HT 2B activation by low-dose LSD were substantial, but short-lived, compared to the cardiotoxin d -fenfluramine. Together, these data provide no evidence of cardiovascular risk associated with prolonged administration of low-dose LSD in mice.